ARKG vs IXJ

Key Takeaways

• ARK Genomic Revolution ETF (ARKG) is an actively managed thematic fund targeting the genomics revolution with a concentrated portfolio of 30-60 mostly small- and mid-cap biotechnology and healthcare innovators, while iShares Global Healthcare ETF (IXJ) is a passively managed fund tracking a broad global healthcare index with approximately 110 large-cap holdings.
• ARKG carries a higher expense ratio of 0.75% compared to IXJ's 0.38%, reflecting its active management and specialized focus versus IXJ's lower-cost passive approach.
• ARKG offers high-conviction exposure to emerging genomics technologies such as gene editing and precision medicine, resulting in greater volatility and potential for outsized returns, whereas IXJ provides diversified access to established pharmaceutical, biotechnology, and healthcare equipment companies worldwide.
• Both ETFs center on the healthcare sector, but ARKG emphasizes disruptive innovation within genomics sub-themes, while IXJ delivers broad sector exposure across developed markets with a heavy U.S. weighting.
• Structural differences include ARKG's active rebalancing based on thematic conviction versus IXJ's rules-based index replication with lower turnover, influencing liquidity profiles and risk characteristics over market cycles.
• Investors seeking thematic growth in genomics may align with ARKG's strategy, while those prioritizing cost efficiency, diversification, and stability may prefer IXJ's broad healthcare representation.

Introduction

ARK Genomic Revolution ETF (ARKG) and iShares Global Healthcare ETF (IXJ) both provide exposure to the healthcare sector but pursue markedly different strategies. ARKG delivers concentrated, active thematic exposure to genomics-driven innovation, while IXJ offers passive, broad-based access to global healthcare equities. These ETFs do not compete directly; instead, they represent alternative approaches for investors targeting healthcare growth, with ARKG appealing to those focused on disruptive technologies and IXJ suiting those seeking diversified sector representation. In the current environment of advancing biotechnology and steady healthcare demand, comparing their structures helps clarify positioning for different risk tolerances and objectives.

ARK Genomic Revolution ETF (ARKG) Overview

ARK Genomic Revolution ETF (ARKG) is an actively managed exchange-traded fund launched in 2014 that seeks long-term capital growth by investing primarily in equity securities of companies involved in the genomics revolution. The fund typically holds 30-60 positions, with a focus on small- and mid-cap companies engaged in gene therapy, bioinformatics, molecular medicine, and related innovations. Top holdings often include companies such as TXG, TWST, TEM, CRSP, and PSNL, reflecting high-conviction bets on genomics leaders. Sector allocation centers overwhelmingly on healthcare, particularly biotechnology and life sciences, with minor exposure to information technology. The expense ratio stands at 0.75%. As an active thematic strategy, ARKG employs discretionary rebalancing driven by fundamental research into disruptive genomics advancements rather than strict index rules, distinguishing it through concentrated bets on emerging technologies.

iShares Global Healthcare ETF (IXJ) Overview

iShares Global Healthcare ETF (IXJ) is a passively managed exchange-traded fund launched in 2001 that seeks to track the performance of the S&P Global 1200 Health Care (Sector) Capped Index. The fund holds approximately 110-114 large-cap global healthcare equities using a representative sampling approach. Top holdings typically feature established names such as LLY, JNJ, ABBV, MRK, and UNH. Sector allocations break down primarily into pharma, biotech, and life sciences (around 70%) and healthcare equipment and services (around 30%). The expense ratio is 0.38%. IXJ maintains geographic diversification with roughly 70% U.S. exposure and meaningful allocations to Switzerland, the United Kingdom, Japan, and other developed markets. As a passive index tracker, it features low turnover and rules-based rebalancing, providing broad, cost-efficient access to the global healthcare sector.

Industry and Thematic Backdrop

The healthcare sector continues to benefit from long-term demographic trends including aging populations and rising chronic disease prevalence, alongside ongoing innovation in biotechnology and precision medicine. Genomics advancements, including gene editing and multi-omic technologies, represent key catalysts for thematic growth, while established pharmaceutical and medical device companies drive steady demand through new drug approvals and healthcare infrastructure needs. Macroeconomic factors such as interest rate environments influence capital allocation within the sector, with biotech innovation often showing sensitivity to funding conditions. Regulatory developments around drug pricing and approval pathways, along with geopolitical supply chain considerations, add layers of complexity. Both ETFs operate within this backdrop, though ARKG amplifies exposure to high-growth genomics sub-themes while IXJ captures the broader sector's defensive and growth characteristics across market cycles.

Performance and Positioning Comparison

In recent market cycles, ARKG has exhibited higher volatility consistent with its concentrated active bets on smaller genomics companies, often amplifying moves tied to biotechnology innovation news and sector rotation toward growth themes. IXJ has demonstrated more stable behavior reflective of its diversified large-cap holdings and lower turnover, providing smoother exposure during earnings seasons and macroeconomic shifts. Relative positioning shows ARKG benefiting from periods of strong genomics momentum while facing greater drawdowns in risk-off environments, whereas IXJ offers resilience through broad global healthcare representation. Over broader timeframes, the active thematic approach of ARKG contrasts with IXJ's passive efficiency, influencing how each responds to interest rate expectations, commodity trends in related materials, and capital flows into healthcare innovation.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Investors comparing ETFs like ARKG and IXJ can leverage this platform to refine their analysis further.

Tickeron AI Verdict

Based on observable factors including lower expense ratio, broader diversification across large-cap global holdings, and consistent passive replication methodology, Tickeron’s AI would currently assign a higher probability of favor to iShares Global Healthcare ETF (IXJ) for investors prioritizing structural efficiency and risk-managed sector exposure. ARKG's active thematic focus offers differentiated potential in genomics innovation but carries elevated concentration and cost considerations that may suit narrower objectives.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations